drugset
drugset / Trial / NCT06507891

A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

NCT06507891 ↗

Phase 1/2 Terminated 30 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung cancer.

Timeline

Start
2020-07-06
Primary completion
2023-08-25
Completion
2024-06-04

Outcome

Outcome not reported

Stopped (Business): “After considering the company's project situation and strategic development direction, it has been decided to terminate this project. The experiment will be terminated for non safety reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — Oral
Subject TQ-A3334 Other / unclassified — Oral

Indications

non-small cell lung carcinoma